GlassScriptPhysician profile
Anthony J Kawa
NPI 1881643955
$4,743.52
in general payments reported to CMS, 2019-2025
21 companies · $765 in 2025
The $765 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $160 · 2021: $320 · 2022: $692 · 2023: $919 · 2024: $1,085 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,768.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,062.80 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $572.22 | 2020-2024 | Watchman Access System, Lux-Dx Insertable Cardiac Monitor, Bodyguardian |
| Abbott Laboratories | $547.10 | 2019-2025 | Aveir, Amplatzer Talisman, Gallant |
| Kestra Medical Technology Services, INC. | $537.41 | 2023-2024 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $302.72 | 2022-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.96 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $244.89 | 2019-2025 | |
| Amgen INC. | $167.32 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $151.87 | 2023-2025 | Verquvo |
| Shockwave Medical, INC | $146.14 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $133.40 | 2022-2023 | Onyx Frontier |
| Philips North America LLC | $127.39 | 2024 | (6571) Eagle Eye |
| Esperion Therapeutics, INC. | $124.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $87.57 | 2022-2025 | Camzyos |
| Heartflow, INC. | $85.09 | 2019-2025 | Ffrct |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventice Services, LLC | $78.86 | 2021 | |
| Chiesi USA, INC. | $45.79 | 2022-2023 | Cleviprex, Kengreal |
| Alnylam Pharmaceuticals INC. | $22.05 | 2025 | Amvuttra |
| Scpharmaceuticals INC. | $18.60 | 2025 | |
| Amarin Pharma, INC. | $15.60 | 2020 | |
| Cardiovascular Systems INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Kawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.